LisenID is advancing cancer healthcare using epigenetic imprinting solutions and AI. Our patent pending technology (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization, QCIGISH) accurately detects 12 types of cancers via minimally invasive biopsy and liquid collection kits. The methodology has already been validated through 7000+ clinical cases in partnership with 20+ hospitals. Our solution offers market leading sensitivity and specificity, which equip healthcare providers with the means to best treat patients earlier and throughout their treatment lifecycle.
Company Details
- Employees
- 5
- Address
- 200 Power Mill Road,
- Industry
- Biotechnology
- Website
- http://lisenid.com
- Keywords
- cancer, oncology, epigenetics, imprinting.
- HQ
- Wilmington, DE
Lisen Imprinting Diagnostics Questions
Lisen Imprinting Diagnostics's website is http://lisenid.com
Lisen Imprinting Diagnostics's LinkedIn profile is https://www.linkedin.com/company/lisenid
Lisen Imprinting Diagnostics has
5 employees.
View email and phone details for 5
employees at Lisen Imprinting Diagnostics.
Lisen Imprinting Diagnostics's industry is
Biotechnology
Lisen Imprinting Diagnostics's top competitors are
Press Ganey,
E15 Group,
Biometis Technology Inc.,
Advisory Board,
Netapp,
Nuubi,
Pagodatree Partners,
The Thier Group,
Ballydel Technologies Inc.,
Atlanticare.
Lisen Imprinting Diagnostics's categories are Biotechnology
